FRACTYL HEALTH, INC.
Develops therapies targeting the root causes of obesity and type 2 diabetes.
GUTS | US
Overview
Corporate Details
- ISIN(s):
- US35168W1036
- LEI:
- Country:
- United States of America
- Address:
- 3 VAN DE GRAAFF DRIVE, 1803 BURLINGTON
- Website:
- https://www.fractyl.com/
- Sector:
- Manufacturing
Description
Fractyl Health, Inc. is a metabolic therapeutics company developing therapies that target the root causes of obesity and type 2 diabetes. The company's approach focuses on interventions in the gut, specifically the duodenum and pancreas, to modify the course of these diseases. Its lead product candidates include two proprietary platforms: Revita, an investigational outpatient endoscopic procedure designed to resurface the duodenal lining, and Rejuva, a gene therapy platform in early development designed to target pancreatic islet cells. Fractyl Health aims to provide long-term, disease-modifying treatments that can potentially reverse metabolic diseases and offer an alternative to chronic drug therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all FRACTYL HEALTH, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FRACTYL HEALTH, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FRACTYL HEALTH, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
